QLT sells Eligard franchise to Tolmar in $230 million deal
This article was originally published in Scrip
Executive Summary
The ocular drug developer QLT has sold its Eligard (leuprolide acetate) product line to Tolmar Holding in a stock deal worth up to $230 million. Privately held Tolmar acquired the prostate cancer asset as part of an agreement to buy the firm's US subsidiary, QLT USA.